MedCity News September 23, 2022
Lyfegen, a startup that provides software for value-based drug contracting, recently raised $8 million in an oversubscribed Series A financing round. With the new funds, the company — which is based in Switzerland and New York — plans to expand its presence in the U.S., where drug costs are the highest in the world.
Specialty medication prices in the U.S. are out of control. Despite making up about 2% of overall prescription volume, specialty drugs accounted for 53% of total annual pharmacy spending last year — up from 27% in 2010 — caused in part by growth in oncology and autoimmune drugs.
Lyfegen, a startup based in Switzerland and New York, thinks the solution to this problem lies within value-based...
Today's Sponsors
Today's Sponsor